Other Pharmaceutical Agents in the Chemoprevention of Prostate Cancer



Prostate cancer is the most commonly diagnosed cancer in the Western world and second commonest cause of death in males. Clinically significant prostate cancer takes two decades to develop. This long natural history of the disease lends itself well to modification by agents—dietary and therapeutic. Prostate cancer represents an ideal target for nutritional prevention due to its long latency, high incidence, tumor marker availability (prostate-specific antigen, PSA), and identifiable preneoplastic lesions and risk groups.


Placebo Cholesterol Zinc Aspirin Testosterone 


  1. 1.
    Graaf MR, et al. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Shannon J, et al. Statins and prostate cancer risk: a case–control study. Am J Epidemiol. 2005;162(4):318–25.PubMedCrossRefGoogle Scholar
  3. 3.
    Murtola TJ, et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer. 2010;127(7):1650–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Dale KM, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Breau RH, et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol. 2010;184(2):494–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1(1):11–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Zha S, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 2001;61(24):8617–23.PubMedGoogle Scholar
  8. 8.
    Palayoor ST, et al. Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2. Clin Cancer Res. 2005;11(19 Pt 1):6980–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Hughes-Fulford M, et al. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res. 2006;66(3):1427–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Dasgupta K, et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J. 2006;12(2):130–5.PubMedGoogle Scholar
  11. 11.
    Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer. 2004;90(1):93–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer. 2010;127(7):1680–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Fleshner N, et al. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol. 1999;161(5):1651–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Jiang C, et al. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res. 2001;61(7):3062–70.PubMedGoogle Scholar
  15. 15.
    Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1171–82.PubMedGoogle Scholar
  16. 16.
    Clark LC, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276(24):1957–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Albanes D, et al. and The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and Beta Carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029–35.Google Scholar
  18. 18.
    Lippman SM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Ofner P, Bosland MC, Vena RL. Differential effects of diethylstilbestrol and estradiol-17 beta in combination with testosterone on rat prostate lobes. Toxicol Appl Pharmacol. 1992;112(2):300–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Leav I, et al. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate. 1989;15(1):23–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Raghow S, et al. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002;62(5):1370–6.PubMedGoogle Scholar
  22. 22.
    Price D, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol. 2006;176(3):965–70. discussion 970–1.PubMedCrossRefGoogle Scholar
  23. 23.
    GTx begins next phase of clinical trials for prostate cancer. Expert Rev Anticancer Ther. 2001;1(3):326.Google Scholar
  24. 24.
    Silberstein JL, Parsons JK. Prostate cancer prevention: concepts and clinical recommendations. Prostate Cancer Prostatic Dis. 2010;13(4):300–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Clinton SK, et al. cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev. 1996;5(10):823–33.PubMedGoogle Scholar
  26. 26.
    Stahl W, et al. cis-trans isomers of lycopene and beta-carotene in human serum and tissues. Arch Biochem Biophys. 1992;294(1):173–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Barber NJ, et al. Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is ­associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer Prostatic Dis. 2006;9(4):407–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Giovannucci E, Clinton SK. Tomatoes, lycopene, and prostate cancer. Proc Soc Exp Biol Med. 1998;218(2):129–39.PubMedGoogle Scholar
  29. 29.
    Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst. 1999;91(4):317–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Gann PH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999;59(6):1225–30.PubMedGoogle Scholar
  31. 31.
    Kirsh VA, et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(1):92–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Peters U, et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case–control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007;16(5):962–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Haseen F, et al. Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis. 2009;12(4):325–32.PubMedCrossRefGoogle Scholar
  34. 34.
    Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int. 2004;94(4):678.PubMedCrossRefGoogle Scholar
  35. 35.
    Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol. 2004;22(5):415–20.PubMedGoogle Scholar
  36. 36.
    Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate. 1998;35(4):285–96.PubMedCrossRefGoogle Scholar
  37. 37.
    Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006;5:17.PubMedCrossRefGoogle Scholar
  38. 38.
    Feng P, et al. Effect of zinc on prostatic tumorigenicity in nude mice. Ann N Y Acad Sci. 2003;1010:316–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Leitzmann MF, et al. Zinc supplement use and risk of prostate ­cancer. J Natl Cancer Inst. 2003;95(13):1004–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Boissier S, et al. Bisphosphonates inhibit breast and prostate ­carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60(11):2949–54.PubMedGoogle Scholar
  41. 41.
    Chandra RK. Excessive intake of zinc impairs immune responses. JAMA. 1984;252(11):1443–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Moyad MA. Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem. Urol Nurs. 2004;24(1):49–52.PubMedGoogle Scholar
  43. 43.
    Cao Y, Cao R, Brakenhielm E. Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem. 2002;13(7):380–90.PubMedCrossRefGoogle Scholar
  44. 44.
    Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 2008;10(3):475–510.PubMedCrossRefGoogle Scholar
  45. 45.
    Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci. 2007;81(7):519–33.PubMedCrossRefGoogle Scholar
  46. 46.
    Hastak K, et al. Ablation of either p21 or Bax prevents p53-­dependent apoptosis induced by green tea polyphenol ­epigallocatechin-3-gallate. FASEB J. 2005;19(7):789–91.PubMedGoogle Scholar
  47. 47.
    Adhami VM, et al. Combined inhibitory effects of green tea ­polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2007;13(5):1611–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001;276(16):13322–30.PubMedCrossRefGoogle Scholar
  49. 49.
    Harper CE, et al. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate. 2007;67(14):1576–89.PubMedCrossRefGoogle Scholar
  50. 50.
    Siddiqui IA, et al. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis. 2006;27(4):833–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Jatoi A, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003;97(6):1442–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Choan E, et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol. 2005;23(2):108–13.PubMedCrossRefGoogle Scholar
  53. 53.
    Kurahashi N, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol. 2008;167(1):71–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Bettuzzi S, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006;66(2):1234–40.PubMedCrossRefGoogle Scholar
  55. 55.
    Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med. 1997;29(2):95–120.PubMedGoogle Scholar
  56. 56.
    Heinonen SM, et al. Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton. J Steroid Biochem Mol Biol. 2003;87(4–5):285–99.PubMedCrossRefGoogle Scholar
  57. 57.
    Shen JC, et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog. 2000;29(2):92–102.PubMedCrossRefGoogle Scholar
  58. 58.
    Aronson WJ, et al. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer. 1999;35(2):130–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Pollard M. Prevention of prostate-related cancers in Lobund-Wistar rats. Prostate. 1999;39(4):305–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Mentor-Marcel R, et al. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001;61(18):6777–82.PubMedGoogle Scholar
  61. 61.
    Hertog MG, et al. Dietary flavonoids and cancer risk in the Zutphen Elderly Study. Nutr Cancer. 1994;22(2):175–84.PubMedCrossRefGoogle Scholar
  62. 62.
    Hertog MG, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995;155(4):381–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Hebert JR, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst. 1998;90(21):1637–47.PubMedCrossRefGoogle Scholar
  64. 64.
    Ganry O. Phytoestrogens and prostate cancer risk. Prev Med. 2005;41(1):1–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Perabo FG, et al. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(1):6–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of UrologyNorfolk and Norwich University HospitalNorwichUK

Personalised recommendations